<DOC>
	<DOC>NCT00724867</DOC>
	<brief_summary>This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.</brief_summary>
	<brief_title>A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States</brief_title>
	<detailed_description>This is a long-term continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States. This study is to evaluate the long-term safety and efficacy of belimumab (LymphoStat-B™) in subjects with SLE disease.</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Have completed the HGS1006C1056 protocol in the United States through Week 72 visit. Be able to receive 1st dose of belimumab for HGS 1006c1066 four weeks after last dose in HGS1006c1056. Have developed any other medical disease or condition that has made the subject unsuitable for this study in the opinion of their physician.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Belimumab</keyword>
	<keyword>SLE</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Lupus</keyword>
	<keyword>Autoimmune Diseases</keyword>
</DOC>